Associated Papers
Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.
Teto G et al.
Scientific Reports, 2017
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
Hu Z et al.
Journal of Virology, 2006
Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK et al.
Antiviral Therapy, 2001
AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
Sharma PL et al.
Virology, 1996
Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.
Lacey SF et al.
Antimicrobial Agents and Chemotherapy, 1994
Select a paper to view details